Literature DB >> 25354145

Incidence and mortality of neurofibromatosis: a total population study in Finland.

Elina Uusitalo1, Jussi Leppävirta2, Anna Koffert3, Sakari Suominen4, Jussi Vahtera5, Tero Vahlberg6, Minna Pöyhönen7, Juha Peltonen8, Sirkku Peltonen3.   

Abstract

Entities:  

Mesh：

Year:  2014        PMID： 25354145     DOI： 10.1038/jid.2014.465

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN： 0022-202X            Impact factor:   8.551


× No keyword cloud information.
  15 in total

1.  Long-term follow-up of von Recklinghausen neurofibromatosis. Survival and malignant neoplasms.

Authors:  S A Sørensen; J J Mulvihill; A Nielsen
Journal:  N Engl J Med       Date:  1986-04-17       Impact factor: 91.245

2.  Neurofibromatosis. Conference statement. National Institutes of Health Consensus Development Conference.

Authors: 
Journal:  Arch Neurol       Date:  1988-05

Review 3.  The pathoetiology of neurofibromatosis 1.

Authors:  Eeva-Mari Jouhilahti; Sirkku Peltonen; Anthony M Heape; Juha Peltonen
Journal:  Am J Pathol       Date:  2011-03-31       Impact factor: 4.307

4.  Mortality in neurofibromatosis 1: in North West England: an assessment of actuarial survival in a region of the UK since 1989.

Authors:  D Gareth R Evans; Catherine O'Hara; Anna Wilding; Sarah L Ingham; Elizabeth Howard; John Dawson; Anthony Moran; Vilka Scott-Kitching; Felicity Holt; Susan M Huson
Journal:  Eur J Hum Genet       Date:  2011-06-22       Impact factor: 4.246

5.  Birth incidence and prevalence of tumor-prone syndromes: estimates from a UK family genetic register service.

Authors:  D G Evans; E Howard; C Giblin; T Clancy; H Spencer; S M Huson; F Lalloo
Journal:  Am J Med Genet A       Date:  2010-02       Impact factor: 2.802

6.  Data quality and quality control of a population-based cancer registry. Experience in Finland.

Authors:  L Teppo; E Pukkala; M Lehtonen
Journal:  Acta Oncol       Date:  1994       Impact factor: 4.089

7.  A clinical study of type 2 neurofibromatosis.

Authors:  D G Evans; S M Huson; D Donnai; W Neary; V Blair; V Newton; R Harris
Journal:  Q J Med       Date:  1992-08

8.  Alteration in a new gene encoding a putative membrane-organizing protein causes neuro-fibromatosis type 2.

Authors:  G A Rouleau; P Merel; M Lutchman; M Sanson; J Zucman; C Marineau; K Hoang-Xuan; S Demczuk; C Desmaze; B Plougastel
Journal:  Nature       Date:  1993-06-10       Impact factor: 49.962

9.  Life expectancy, mortality and prognostic factors in neurofibromatosis type 1. A twelve-year follow-up of an epidemiological study in Göteborg, Sweden.

Authors:  M Zöller; B Rembeck; H O Akesson; L Angervall
Journal:  Acta Derm Venereol       Date:  1995-03       Impact factor: 4.437

10.  Mortality associated with neurofibromatosis 1: a cohort study of 1895 patients in 1980-2006 in France.

Authors:  Tu Anh Duong; Emilie Sbidian; Laurence Valeyrie-Allanore; Cédric Vialette; Salah Ferkal; Smaïl Hadj-Rabia; Christophe Glorion; Stanislas Lyonnet; Michel Zerah; Isabelle Kemlin; Diana Rodriguez; Sylvie Bastuji-Garin; Pierre Wolkenstein
Journal:  Orphanet J Rare Dis       Date:  2011-05-04       Impact factor: 4.123
View more
  63 in total

1.  Identification of an atypical microdeletion generating the RNF135-SUZ12 chimeric gene and causing a position effect in an NF1 patient with overgrowth.

Authors:  Luca Ferrari; Giulietta Scuvera; Arianna Tucci; Donatella Bianchessi; Francesco Rusconi; Francesca Menni; Elena Battaglioli; Donatella Milani; Paola Riva
Journal:  Hum Genet       Date:  2017-08-03       Impact factor: 4.132

Review 2.  An update on the central nervous system manifestations of neurofibromatosis type 1.

Authors:  J Stephen Nix; Jaishri Blakeley; Fausto J Rodriguez
Journal:  Acta Neuropathol       Date:  2019-04-08       Impact factor: 17.088

3.  Genetic basis of neurofibromatosis type 1 and related conditions, including mosaicism.

Authors:  Eric Legius; Hilde Brems
Journal:  Childs Nerv Syst       Date:  2020-06-29       Impact factor: 1.475

4.  The effect of estradiol, testosterone, and human chorionic gonadotropin on the proliferation of Schwann cells with NF1 +/- or NF1 -/- genotype derived from human cutaneous neurofibromas.

Authors:  Paula Pennanen; Sirkku Peltonen; Roope A Kallionpää; Juha Peltonen
Journal:  Mol Cell Biochem       Date:  2017-11-28       Impact factor: 3.396

5.  Neurofibromatosis Type 1 Implicates Ras Pathways in the Genetic Architecture of Neurodevelopmental Disorders.

Authors:  Jessica A Kaczorowski; Taylor F Smith; Amanda M Shrewsbury; Leah R Thomas; Valerie S Knopik; Maria T Acosta
Journal:  Behav Genet       Date:  2020-02-05       Impact factor: 2.805

Review 6.  Malignant Peripheral Nerve Sheath Tumors: From Epigenome to Bedside.

Authors:  Justin Korfhage; David B Lombard
Journal:  Mol Cancer Res       Date:  2019-04-25       Impact factor: 5.852

Review 7.  Spinal manifestations of Neurofibromatosis type 1.

Authors:  Ben Shofty; Ori Barzilai; Morsi Khashan; Zvi Lidar; Shlomi Constantini
Journal:  Childs Nerv Syst       Date:  2020-06-20       Impact factor: 1.475

8.  Peri-gestational risk factors for pediatric brain tumors in Neurofibromatosis Type 1.

Authors:  Kimberly J Johnson; Nancy L Zoellner; David H Gutmann
Journal:  Cancer Epidemiol       Date:  2016-03-25       Impact factor: 2.984

9.  Bone Status According to Neurofibromatosis Type 1 Phenotype: A Descriptive Study of 60 Women in France.

Authors:  Maud Jalabert; Salah Ferkal; Jean-Claude Souberbielle; Emilie Sbidian; Arthur Mageau; Florent Eymard; Philippe Le Corvoisier; Laurence Allanore; Xavier Chevalier; Pierre Wolkenstein; Sandra Guignard
Journal:  Calcif Tissue Int       Date:  2021-02-08       Impact factor: 4.333

10.  Racial/Ethnic Differences in Pediatric Brain Tumor Diagnoses in Patients with Neurofibromatosis Type 1.

Authors:  Salmafatima S Abadin; Nancy L Zoellner; Melody Schaeffer; Bree Porcelli; David H Gutmann; Kimberly J Johnson
Journal:  J Pediatr       Date:  2015-05-28       Impact factor: 4.406
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.